Hyderabad-based Suven plans to buy US-based Rising Pharma’s assets

By: |
Published: March 9, 2019 3:47:06 AM

Suven Life entered into a ‘stalking-horse’ asset purchase agreement to buy the assets of Rising Pharmaceuticals and its subsidiaries.

Shore Suven Pharma is a joint venture between Suven Life Sciences and Shore Pharma Investments of US.

Biopharmaceutical company Suven Life Sciences has signed an agreement to buy the assets of US-based Aceto’s Rising Pharmaceuticals and its subsidiaries through its joint venture partner Shore Suven Pharma. Suven has agreed to pay gross cash proceeds of $15 million for the assets. It will also take on the operating liabilities and customer obligations related to the acquired business on a cash-free and debt-free basis.

Suven Life, which provides contract research and manufacturing services (CRAMS) to global life sciences companies, entered into a ‘stalking-horse’ asset purchase agreement to buy the assets of Rising Pharmaceuticals and its subsidiaries, it said in a regulatory filing. A ‘stalking-horse’ asset purchase agreement is a bid on the assets of a bankrupt company.

Read | Rakesh Jhunjhunwala says still in the game for Star Health, denies report of pulling out

The transaction is subject to court-approved bidding process under Section 363 of US Bankruptcy Code, the filing added. Shore Suven Pharma is a joint venture between Suven Life Sciences and Shore Pharma Investments of US.

“This potential acquisition of Rising’s assets would transform Shore Suven Pharma into a strong US generic pharmaceutical company. Leveraging Rising’s extensive product portfolio to become vertically integrated with our already world class API and finished dose manufacturing capabilities will enable us to better serve US customers,” Suven Life Sciences CEO and chairman Venkat Jasti said.

Read | Baba Ramdev plays desi card on HUL; calls for boycott after Brooke Bond Kumbh Mela ad fiasco

Vimal Kavuru, who will serve as CEO of Shore Suven Pharma said the opportunity to work with Rising’s suppliers and employees to ensure continuity of product supply to customers in connection with this proposed integration will be the company’s top priority.

“We have an exceptional generic pharmaceutical management team ready to facilitate a smooth transition while maximising the value of these assets. We look forward to working towards a successful closing,” he added.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Next Stories
1Coal India needs to up supply by at least 8% to meet GoM plan: Report
2NCLAT directs NCLT to decide on JSW’s bid for Bhushan Power & Steel by March 31
3Pune Smart City to organise cyber-security hackathon in partnership with DSCI